NasdaqGS:REGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: REGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.5%

REGN

0.5%

US Biotechs

3.0%

US Market


1 Year Return

101.6%

REGN

27.3%

US Biotechs

9.9%

US Market

Return vs Industry: REGN exceeded the US Biotechs industry which returned 27.6% over the past year.

Return vs Market: REGN exceeded the US Market which returned 9.5% over the past year.


Shareholder returns

REGNIndustryMarket
7 Day7.5%0.5%3.0%
30 Day16.6%9.2%8.2%
90 Day32.8%12.8%0.4%
1 Year101.6%101.6%28.6%27.3%12.4%9.9%
3 Year27.6%27.6%34.7%30.2%31.0%22.3%
5 Year16.5%16.5%-1.9%-7.8%58.1%40.3%

Price Volatility Vs. Market

How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

29.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: REGN ($612.81) is trading above our estimate of fair value ($457.86)

Significantly Below Fair Value: REGN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: REGN is poor value based on its PE Ratio (29.4x) compared to the Biotechs industry average (18.6x).

PE vs Market: REGN is poor value based on its PE Ratio (29.4x) compared to the US market (15.8x).


Price to Earnings Growth Ratio

PEG Ratio: REGN is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: REGN is overvalued based on its PB Ratio (5.6x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?

9.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's forecast earnings growth (9.1% per year) is above the savings rate (2.2%).

Earnings vs Market: REGN's earnings (9.1% per year) are forecast to grow slower than the US market (22% per year).

High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: REGN's revenue (8.4% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: REGN's revenue (8.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be high in 3 years time (21.7%)


Next Steps

Past Performance

How has Regeneron Pharmaceuticals performed over the past 5 years?

32.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REGN has high quality earnings.

Growing Profit Margin: REGN's current net profit margins (27.4%) are lower than last year (36.9%).


Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown significantly by 32.1% per year over the past 5 years.

Accelerating Growth: REGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: REGN had negative earnings growth (-6%) over the past year, making it difficult to compare to the Biotechs industry average (-4.5%).


Return on Equity

High ROE: REGN's Return on Equity (18.8%) is considered low.


Next Steps

Financial Health

How is Regeneron Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($8.6B) exceed its short term liabilities ($2.1B).

Long Term Liabilities: REGN's short term assets ($8.6B) exceed its long term liabilities ($1.6B).


Debt to Equity History and Analysis

Debt Level: REGN is debt free.

Reducing Debt: REGN has no debt compared to 5 years ago when its debt to equity ratio was 4.7%.

Debt Coverage: REGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: REGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Leonard Schleifer (66yo)

32.42yrs

Tenure

US$21,455,117

Compensation

Dr. Leonard S. Schleifer, M.D., Ph.D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P ...


CEO Compensation Analysis

Compensation vs Market: Leonard's total compensation ($USD21.46M) is above average for companies of similar size in the US market ($USD11.65M).

Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Leonard Schleifer
Co-Founder32.42yrsUS$21.46m2.27% $1.4b
George Yancopoulos
Co-Founder19.42yrsUS$20.66m1.17% $730.0m
Robert Landry
Executive VP of Finance & CFO6.67yrsUS$7.93m0.024% $15.1m
Andrew Murphy
Executive Vice President of Research1.42yrsUS$9.52m0.053% $33.2m
Daniel Van Plew
Executive VP and GM of Industrial Operations & Product Supply12.17yrsUS$7.83m0.029% $18.3m
Patrice Gilooly
Senior Vice President of Quality Assurance & Operations0.42yrno datano data
Gerald Underwood
Senior Vice President of Technical Operations0.42yrno datano data
Justin Holko
Vice President of Investor Relations1yrno datano data
Joseph LaRosa
Executive VP8.75yrsUS$3.38m0.015% $9.0m
Beth Levine
Senior VP1.42yrsno datano data

2.5yrs

Average Tenure

59yo

Average Age

Experienced Management: REGN's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Leonard Schleifer
Co-Founder32.42yrsUS$21.46m2.27% $1.4b
George Yancopoulos
Co-Founder19.42yrsUS$20.66m1.17% $730.0m
Christine Poon
Independent Director9.58yrsUS$719.99k0.00078% $485.4k
Pindaros Vagelos
Chairman of the Board25.42yrsUS$6.10m0.53% $330.1m
Arthur Ryan
Independent Director17.42yrsUS$724.99k0.028% $17.7m
Michael Brown
Independent Director29yrsUS$724.99k0.018% $11.0m
Joseph Goldstein
Independent Director29yrsUS$709.99k0.0069% $4.3m
George Sing
Independent Director32.42yrsUS$722.99k0.13% $79.5m
Marc Tessier-Lavigne
Independent Director8.58yrsUS$699.99k0.0012% $728.1k
Bonnie Bassler
Independent Director3.75yrsUS$709.99kno data

22.4yrs

Average Tenure

68.5yo

Average Age

Experienced Board: REGN's board of directors are seasoned and experienced ( 22.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: REGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Regeneron Pharmaceuticals, Inc.
  • Ticker: REGN
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$62.233b
  • Shares outstanding: 101.55m
  • Website: https://www.regeneron.com

Number of Employees


Location

  • Regeneron Pharmaceuticals, Inc.
  • 777 Old Saw Mill River Road
  • Tarrytown
  • New York
  • 10591
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 1991
RGODB (Deutsche Boerse AG)YesCommon StockDEEURApr 1991
REGNSWX (SIX Swiss Exchange)YesCommon StockCHCHFApr 1991
0R2MLSE (London Stock Exchange)YesCommon StockGBUSDApr 1991
REGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNApr 1991
REGNWBAG (Wiener Boerse AG)YesCommon StockATEURApr 1991
RGOETLX (Eurotlx)YesCommon StockITEURApr 1991
REGN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 1 REP 0.2 COM USD0.001BRBRLMay 2019

Biography

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a strategic collaboration with Zai Lab Limited. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 03:56
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.